Intrust Bank NA Acquires 1,391 Shares of Sanofi (NASDAQ:SNY)

Intrust Bank NA lifted its holdings in Sanofi (NASDAQ:SNY) by 5.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,978 shares of the company’s stock after purchasing an additional 1,391 shares during the quarter. Intrust Bank NA’s holdings in Sanofi were worth $1,349,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in SNY. Synergy Asset Management LLC bought a new position in Sanofi in the fourth quarter valued at approximately $25,000. McClarren Financial Advisors Inc. grew its stake in shares of Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after buying an additional 543 shares in the last quarter. Lee Danner & Bass Inc. acquired a new position in Sanofi during the fourth quarter worth $31,000. Sunbelt Securities Inc. raised its position in Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after acquiring an additional 313 shares in the last quarter. Finally, Sierra Ocean LLC acquired a new stake in Sanofi in the fourth quarter valued at $44,000. Institutional investors and hedge funds own 14.04% of the company’s stock.

Analyst Upgrades and Downgrades

SNY has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Finally, The Goldman Sachs Group began coverage on Sanofi in a report on Friday, March 21st. They set a “neutral” rating and a $65.00 price target for the company. Three equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $62.50.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $55.82 on Friday. The firm has a market cap of $141.66 billion, a P/E ratio of 22.42, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. The business’s 50 day moving average is $55.13 and its 200-day moving average is $52.79. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. Sanofi has a 1-year low of $45.22 and a 1-year high of $60.12.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Equities research analysts predict that Sanofi will post 4.36 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.